Accelerated Pathway Opens for GSK’s Pruritus Solution in China’s Rare Liver Disease Population
GlaxoSmithKline has achieved a significant regulatory milestone as China's National Medical Products Administration granted priority review status to linerixibat, an investigational treatment for cholestatic pruritus associated with primary biliary cholangitis.…
Continue Reading
Accelerated Pathway Opens for GSK’s Pruritus Solution in China’s Rare Liver Disease Population
